1628 / 1708
study, the neuro-psychometric data, and the PNET5 study in
progress.
Future studies should include both a more global overview of
executive function by assessing it not only in everyday life, as we
did here, but also in the testing situation and also more detailed
auxology, including sitting height and pubertal staging.
References
1.
Armstrong GT, Jain N, Liu W, et al. Region-specific radiotherapy and neuropsychological outcomes in adult survivors of childhood CNS malignancies. Neuro Oncol 2010;12:1173-1186.2.
Boman KK, Lindblad F, Hjern A. Long-term outcomes of childhood cancer survivors in Sweden: A population-based study of education, employment, and income. Cancer 2010;116:1385-1391.3.
Vinchon M, Baroncini M, Leblond P, et al. Morbidity and tumor- related mortality among adult survivors of pediatric brain tumors: A review. Childs Nervous System 2011;27:697-704.4.
Armstrong GT. Long-term survivors of childhood central nervous system malignancies: The experience of the Childhood Cancer Sur- vivor Study. Eur J Paediatr Neurol 2010;14:298-303.5.
Boman KK, Hoven E, Andclair M, et al. Health and persistent functional late effects in adult survivors of childhood CNS tumours: A population-based cohort study. Eur J Cancer 2009;45:2552-2561.6.
Frange P, Alapetite C, Gaboriaud G, et al. From childhood to adulthood: Long-term outcome of medulloblastoma patients. The Institut Curie experience (1980-2000). J Neurooncol 2009;95:271- 279.7.
Ribi K, Relly C, Landolt MA, et al. Outcome of medulloblastoma in children: Long-term complications and quality of life. Neuro- pediatrics 2005;36:357-365.8.
Maddrey AM, Bergeron JA, Lombardo ER, et al. Neuropsychologi- cal performance and quality of life of 10 year survivors of childhood medulloblastoma. J Neurooncol 2005;72:245-253.9.
Mulhern RK, Merchant TE, Gajjar A, et al. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 2004;5:399-408.10.
Wolfe KR, Madan-Swain A, Kana RK. Executive dysfunction in pediatric posterior fossa tumor survivors: A systematic literature review of neurocognitive deficits and interventions. Dev Neuro- psychol 2012;37:153-175.11.
Ellenberg L, Liu Q, Gioia G, et al. Neurocognitive status in long-term survivors of childhood CNS malignancies: A report from the Childhood Cancer Survivor Study. Neuropsychology 2009;23:705- 717.12.
Vaquero E, Gomez CM, Quintero EA, et al. Differential prefrontal- like deficit in children after cerebellar astrocytoma and medullo- blastoma tumor. Behav Brain Functions 2008;4:18.13.
Mulhern RK, Palmer SL, Merchant TE, et al. Neurocognitive con- sequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol 2005;23:5511-5519.14.
Pettorini BL, Narducci A, de Carlo A, et al. Thyroid neoplasm after central nervous system irradiation for medulloblastoma in childhood: Report of two cases. Childs Nerv Syst 2009;25:631-634.15.
Ogilvy-Stuart AL, Shalet SM. Growth and puberty after growth hormone treatment after irradiation for brain tumours. Arch Dis Childhood 1995;73:141-146.16.
Ogilvy-Stuart AL, Shalet SM, Gattamaneni HR. Thyroid function after treatment of brain tumors in children. J Pediatr 1991;119:733- 737.17.
Hartsell WF, Hanson WR, Conterato DJ, et al. Hyperfractionation decreases the deleterious effects of conventional radiation fraction- ation on vertebral growth in animals. Cancer 1989;63:2452-2455.18.
Spoudeas HA. Growth following malignancy. Best Pract Res Clin Endocrinol Metab 2002;16:561-590.19.
Gurney JG, Kadan-Lottick NS, Packer RJ, et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors d Childhood Cancer Survivor Study. Cancer 2003;97: 663-673.20.
Grenier Y, Tomita T, Marymont MH, et al. Late postirradiation occlusive vasculopathy in childhood medulloblastoma d report of two cases. J Neurosurg 1998;89:460-464.21.
Maher CO, Raffel C. Early vasculopathy following radiation in a child with medulloblastoma. Pediatr Neurosurg 2000;32:255-258.22.
Salih ISM, Higgins NJN, Warburton EA, et al. Lacunar stroke attributable to radiation-induced intracranial arteriopathy. Eur J Neurol 2007;14:937-939.23.
Amoroso L, Grill J, Bhangoo R, et al. High rate of second tumors in medulloblastoma long-term survivors in the cohort “the first 100” of the Gustave Roussy Institute. Neuro Oncol 2008;10. 475 e 475.24.
Edelstein K, Spiegler BJ, Fung S, et al. Early aging in adult survivors of childhood medulloblastoma: Long-term neurocognitive, func- tional, and physical outcomes. Neuro Oncol 2011;13:536-545.25.
Koksal Y, Toy H, Unal E, et al. Pilocytic astrocytoma developing at the site of a previously treated medulloblastoma in a child. Childs Nerv Syst 2008;24:289-292.26.
Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989;62:679-694.27.
Carrie C, Grill J, Figarella-Branger D, et al. Online quality control, hyperfractionated radiotherapy alone and reduced boost volume for standard risk medulloblastoma: Long-term results of MSFOP 98. J Clin Oncol 2009;27:1879-1883.28.
Gupta T, Jalali R, Goswami S, et al. Early clinical outcomes demonstrate preserved cognitive function in children with average- risk medulloblastoma when treated with hyperfractionated radiation therapy. Int J Radiat Oncol Biol Phys 2012;83:1534-1540.29.
Kieffer-Renaux V, Viguier D, Raquin MA, et al. Therapeutic schedules influence the pattern of intellectual decline after irradiation of poste- rior fossa tumors. Pediatr Blood Cancer 2005;45:814-819.30.
Lannering B, Rutkowski S, Doz F, et al. Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard- risk medulloblastoma: Results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol 2012;30:3187-3193.31.
Embry L, Annett RD, Kunin-Batson A, et al. Implementation of multi-site neurocognitive assessments within a pediatric cooperative group: Can it be done? Pediatr Blood Cancer 2012;59:536-539.32.
Bull KS, Spoudeas HA, Yadegarfar G, et al. Reduction of health status 7 years after addition of chemotherapy to craniospinal irradi- ation for medulloblastoma: A follow-up study in PNET 3 trial sur- vivors d on behalf of the CCLG (formerly UKCCSG). J Clin Oncol 2007;25:4239-4245.33.
Gioia GA, Isquith PK, Guy SC, et al. Behavior Rating Inventory of Ex- ecutive Function. Lutz, FL: Psychological Assessment Resources; 2000.34.
Feeny D, Furlong W, Barr RD, et al. A comprehensive multiattribute system for classifying the health status of survivors of childhood cancer. J Clin Oncol 1992;10:923-928.35.
Goodman R. The strengths and difficulties questionnaire: A research note. J Child Psychol Psychiatr Allied Disciplines 1997;38:581-586.36.
Varni JW, Seid M, Rode CA. The PedsQL: Measurement model for the pediatric quality of life inventory. Med Care 1999;37:126-139.37.
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Or- ganization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.38.
Merchant TE, Rose SR, Bosley C, et al. Growth hormone secretion after conformal radiation therapy in pediatric patients with localized brain tumors. J Clin Oncol 2011;29:4776-4780.39.
Freeman JV, Cole TJ, Chinn S, et al. Cross-sectional stature and weight reference curves for the UK 1990. Arch Dis Childhood 1995; 73:17-24.40.
Glaser A, Kennedy C, Punt J, et al. Standardized quantitative assessment of brain tumor survivors treated within clinical trials in childhood. Int J Cancer 1999;77-82.Volume 88 Number 2 2014
Quality of survival in the PNET4 study
299